Detail akcie Black Diamond Rg online

Business Summary: Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Black Diamond Therapeutics Inc revenues increased from $0K to $70M. Net income totaled $37.5M vs. loss of $53.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Research and development (inclusive decrease of 33% to $24.9M (expense).